A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.
View/ Open
Date
2022-07-22ICR Author
Author
Torr, B
Jones, C
Choi, S
Allen, S
Kavanaugh, G
Hamill, M
Garrett, A
MacMahon, S
Loong, L
Reay, A
Yuan, L
Valganon Petrizan, M
Monson, K
Perry, N
Fallowfield, L
Jenkins, V
Gold, R
Taylor, A
Gabe, R
Wiggins, J
Lucassen, A
Manchanda, R
Gandhi, A
George, A
Hubank, M
Kemp, Z
Evans, DG
Bremner, S
Turnbull, C
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Germline genetic testing affords multiple opportunities for women with breast cancer, however, current UK NHS models for delivery of germline genetic testing are clinician-intensive and only a minority of breast cancer cases access testing. METHODS: We designed a rapid, digital pathway, supported by a genetics specialist hotline, for delivery of germline testing of BRCA1/BRCA2/PALB2 (BRCA-testing), integrated into routine UK NHS breast cancer care. We piloted the pathway, as part of the larger BRCA-DIRECT study, in 130 unselected patients with breast cancer and gathered preliminary data from a randomised comparison of delivery of pretest information digitally (fully digital pathway) or via telephone consultation with a genetics professional (partially digital pathway). RESULTS: Uptake of genetic testing was 98.4%, with good satisfaction reported for both the fully and partially digital pathways. Similar outcomes were observed in both arms regarding patient knowledge score and anxiety, with <5% of patients contacting the genetics specialist hotline. All progression criteria established for continuation of the study were met. CONCLUSION: Pilot data indicate preliminary demonstration of feasibility and acceptability of a fully digital pathway for BRCA-testing and support proceeding to a full powered study for evaluation of non-inferiority of the fully digital pathway, detailed quantitative assessment of outcomes and operational economic analyses. TRIAL REGISTRATION NUMBER: ISRCTN87845055.
Collections
Subject
genetic counseling
genetic predisposition to disease
genetic testing
genetics
health care facilities, manpower, and services
Research team
Translational Genetics
Language
eng
Date accepted
2022-07-03
License start date
2022-07-22
Citation
Journal of Medical Genetics, 2022, pp. jmedgenet-2022-108655 -
Publisher
BMJ PUBLISHING GROUP
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Catch my drift? Making sense of genomic intra-tumour heterogeneity.
Sottoriva, A; Barnes, CP; Graham, TA (ELSEVIER, 2017-04-01)The cancer genome is shaped by three components of the evolutionary process: mutation, selection and drift. While many studies have focused on the first two components, the role of drift in cancer evolution has received ... -
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; et al. (CELL PRESS, 2017-09-12)Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ... -
Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2.
Studd, JB; Vijayakrishnan, J; Yang, M; Migliorini, G; Paulsson, K; et al. (NATURE PORTFOLIO, 2017-03-03)Despite high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL) being the most common subgroup of paediatric ALL, its aetiology remains unknown. Genome-wide association studies have demonstrated association at 10q21.2. ...